{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:37:54Z","timestamp":1794609474154,"version":"4.9.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","funder":[{"name":"Intramural Research program"},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["ES101074"],"award-info":[{"award-number":["ES101074"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["ES1010081"],"award-info":[{"award-number":["ES1010081"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cure JM Foundation","id":[{"id":"https:\/\/ror.org\/04ts2vz32","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Myositis-specific autoantibodies have defined distinct phenotypes of patients with juvenile myositis (JIIM). We assessed the frequency and clinical significance of anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody-associated JIIM in a North American registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective examination of the characteristics of 35 JIIM patients with anti-MDA5 autoantibodies was performed, and differences from other myositis-specific autoantibody groups were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Anti-MDA5 autoantibodies were present in 35\/453 (7.7%) of JIIM patients and associated with older age at diagnosis, and lower serum creatine kinase and aldolase levels. Patients with anti-MDA5 autoantibodies had more frequent weight loss, adenopathy, arthritis, interstitial lung disease (ILD), and less frequent falling compared with anti-transcriptional intermediary factor 1 (TIF1), anti-nuclear matrix protein 2 (NXP2)\u00a0and myositis-specific autoantibody\/myositis-associated autoantibody-negative patients. They had a different season of diagnosis and less frequent mechanic\u2019s hands and ILD compared with those with anti-synthetase autoantibodies. Anti-MDA5 patients received fewer medications compared with anti-TIF1, and corticosteroid treatment was shorter compared with anti-TIF1 and anti-nuclear matrix protein 2 autoantibody groups. The frequency of remission was higher in anti-MDA5 than anti-synthetase autoantibody-positive JIIM. In multivariable analyses, weight loss, arthritis and arthralgia were most strongly associated with anti-MDA5 autoantibody-positive JIIM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Anti-MDA5 JIIM is a distinct subset, with frequent arthritis, weight loss, adenopathy and less severe myositis, and is also associated with ILD. Anti-MDA5 is distinguished from anti-synthetase autoantibody-positive JIIM by less frequent ILD, lower creatine kinase levels and differing seasons of diagnosis. Anti-MDA5 has comparable outcomes, but with the ability to discontinue steroids more rapidly and less frequent flares compared with anti-TIF1 autoantibodies, and more frequent remission compared with anti-synthetase JIIM patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa429","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T07:19:09Z","timestamp":1592983149000},"page":"1839-1849","source":"Crossref","is-referenced-by-count":55,"title":["Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America"],"prefix":"10.1093","volume":"60","author":[{"given":"Gulnara","family":"Mamyrova","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kishi","sequence":"additional","affiliation":[{"name":"Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shi","sequence":"additional","affiliation":[{"name":"Biostatistics & Computational Biology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira N","family":"Targoff","sequence":"additional","affiliation":[{"name":"Veteran\u2019s Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M","family":"Huber","sequence":"additional","affiliation":[{"name":"IWK Health Centre and Dalhousie University, Halifax, NS, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo V","family":"Curiel","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick W","family":"Miller","sequence":"additional","affiliation":[{"name":"Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G","family":"Rider","sequence":"additional","affiliation":[{"name":"Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Childhood Myositis Heterogeneity Collaborative Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"2021040620371574000_keaa429-B1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Rider","year":"2013","journal-title":"Medicine"},{"key":"2021040620371574000_keaa429-B2","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/acr.22212","article-title":"Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies","volume":"66","author":"Huber","year":"2014","journal-title":"Arthritis Care Res"},{"key":"2021040620371574000_keaa429-B3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/art.39466","article-title":"Association of myositis autoantibodies, clinical features, and environmental exposures at illness onset with disease course in juvenile myositis","volume":"68","author":"Habers","year":"2016","journal-title":"Arthritis Rheum"},{"key":"2021040620371574000_keaa429-B4","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibody to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021040620371574000_keaa429-B5","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021040620371574000_keaa429-B6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/rheumatology\/kep375","article-title":"The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody","volume":"49","author":"Nakashima","year":"2010","journal-title":"Rheumatology"},{"key":"2021040620371574000_keaa429-B7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","article-title":"Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis","volume":"158","author":"Kobayashi","year":"2011","journal-title":"J Pediatr"},{"key":"2021040620371574000_keaa429-B8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14397595.2018.1452353","article-title":"Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies","volume":"29","author":"Ueki","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2021040620371574000_keaa429-B9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archdermatol.2011.52","article-title":"Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis","volume":"147","author":"Hamaguchi","year":"2011","journal-title":"Arch Dermatol"},{"key":"2021040620371574000_keaa429-B10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology"},{"key":"2021040620371574000_keaa429-B11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2010.09.016","article-title":"The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study","volume":"65","author":"Fiorentino","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2021040620371574000_keaa429-B12","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2021040620371574000_keaa429-B13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2021040620371574000_keaa429-B14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3899\/jrheum.160682","article-title":"Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis","volume":"44","author":"Moghadam-Kia","year":"2017","journal-title":"J Rheumatol"},{"key":"2021040620371574000_keaa429-B15","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/acr.21992","article-title":"Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum","volume":"65","author":"Hall","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2021040620371574000_keaa429-B16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/03009742.2017.1334814","article-title":"Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review","volume":"47","author":"Hoa","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2021040620371574000_keaa429-B17","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00296-019-04398-2","article-title":"Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review","volume":"39","author":"Huang","year":"2019","journal-title":"Rheumatol Int"},{"key":"2021040620371574000_keaa429-B18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis. Part 1 and 2","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2021040620371574000_keaa429-B19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","article-title":"The clinical phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Shah","year":"2013","journal-title":"Medicine"},{"key":"2021040620371574000_keaa429-B20","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.semarthrit.2018.03.016","article-title":"Medications received by patients with juvenile dermatomyositis","volume":"48","author":"Kishi","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2021040620371574000_keaa429-B21","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021040620371574000_keaa429-B22","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1093\/rheumatology\/keq277","article-title":"Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"49","author":"Rider","year":"2010","journal-title":"Rheumatology"},{"key":"2021040620371574000_keaa429-B23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1037\/0022-006X.55.4.534","article-title":"Assessment of major and daily stressful events during adolescence: adolescent Perceived Events Scale","volume":"55","author":"Compas","year":"1987","journal-title":"J Consult Clin Psychol"},{"key":"2021040620371574000_keaa429-B24","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/art.37985","article-title":"Ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis","volume":"65","author":"Shah","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021040620371574000_keaa429-B25","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/01.md.0000189818.63141.8c","article-title":"Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians","volume":"84","author":"O\u2019Hanlon","year":"2005","journal-title":"Medicine"},{"key":"2021040620371574000_keaa429-B26","doi-asserted-by":"crossref","DOI":"10.1142\/4031","volume-title":"Topics in Circular Statistics, Sections 3.3.2 and 3.4.1","author":"Jammalamadaka","year":"2001"},{"key":"2021040620371574000_keaa429-B27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2307\/3001775","article-title":"Tests for linear trends in proportions and frequencies","volume":"11","author":"Armitage","year":"1955","journal-title":"Biometrics"},{"key":"2021040620371574000_keaa429-B28","author":"Malley","year":"2011"},{"key":"2021040620371574000_keaa429-B29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"2021040620371574000_keaa429-B30","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/rheumatology\/key190","article-title":"Features distinguishing clinically amyopathic juvenile dermatomyositis (CAJDM) from juvenile dermatomyositis (JDM)","volume":"57","author":"Mamyrova","year":"2018","journal-title":"Rheumatology"},{"key":"2021040620371574000_keaa429-B31","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1080\/14397595.2018.1511025","article-title":"Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: experience at a single center in Japan","volume":"29","author":"Iwata","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2021040620371574000_keaa429-B32","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s11606-016-3769-0","article-title":"Anti-MDA5-postive dermatomyositis presenting as fever of unknown origin","volume":"31","author":"Lee","year":"2016","journal-title":"J Gen Intern Med"},{"key":"2021040620371574000_keaa429-B33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol"},{"key":"2021040620371574000_keaa429-B34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","article-title":"Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis","volume":"54","author":"Kobayashi","year":"2015","journal-title":"Rheumatology"},{"key":"2021040620371574000_keaa429-B35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrrheum.2018.48","article-title":"Risk factors and disease mechanisms in myositis","volume":"14","author":"Miller","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2021040620371574000_keaa429-B36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11926-018-0798-1","article-title":"Anti-MDA5 antibody spectrum in Western world","volume":"20","author":"Moghadam-Kia","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"2021040620371574000_keaa429-B37","doi-asserted-by":"crossref","first-page":"R214","DOI":"10.1186\/ar3547","article-title":"Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in Central Japan","volume":"13","author":"Muro","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2021040620371574000_keaa429-B38","author":"Nishina"},{"key":"2021040620371574000_keaa429-B39","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1002\/art.34657","article-title":"Association of HLA-DRB1*0101\/*0405 with susceptibility to anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis in the Japanese population","volume":"64","author":"Gono","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/4\/1839\/36912674\/keaa429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/4\/1839\/36912674\/keaa429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T19:39:11Z","timestamp":1617737951000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/4\/1839\/5952402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,11,3]]},"published-print":{"date-parts":[[2021,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa429","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,11,3]]}}}